PYC Therapeutics Ltd traded at 0.08 this Tuesday May 17th, decreasing 0.01 or 6.17 percent since the previous trading session. Looking back, over the last four weeks, PYC Therapeutics Ltd lost 21.65 percent. Over the last 12 months, its price fell by 47.59 percent. Looking ahead, we forecast PYC Therapeutics Ltd to be priced at 0.08 by the end of this quarter and at 0.07 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
0.08
Daily Change
-6.17%
Yearly
-47.59%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Avita Therapeutics Inc 1.57 -0.03 -1.57% -65.42%
Opthea Ltd 1.22 0.03 2.52% -13.48%
Paradigm Biopharmaceuticals Ltd 1.15 0.02 1.33% -46.24%
Pacific Edge 0.80 0.01 1.27% -28.57%
Telix Pharmaceuticals Ltd 3.90 -0.04 -1.02% -6.02%


PYC Therapeutics Ltd
PYC Therapeutics Limited is an Australia-based drug-development company, which offers ribonucleic acid (RNA) therapeutics to meet unmet needs in disease. The Company has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The Company develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The Company's discovery and laboratory operations are located in Australia.